Effect of recombinant human interleukin 11 on the platelet after hematopoietic stem cell transplantation in patients with leukemia.
- Author:
Ya-jing XU
1
;
Fang-ping CHEN
;
Xiao-lin LI
;
Xie-lan ZHAO
;
Qun HE
Author Information
1. Department of Hematology,Xiangya Hospital,Central South University,Changsha 410008,China. xuyajingdr2004@163.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Interleukin-11;
genetics;
therapeutic use;
Leukemia;
blood;
surgery;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
blood;
surgery;
Leukemia, Myeloid, Acute;
blood;
surgery;
Male;
Middle Aged;
Platelet Count;
Recombinant Proteins;
therapeutic use;
Thrombocytopenia;
drug therapy;
Treatment Outcome
- From:
Journal of Central South University(Medical Sciences)
2007;32(3):433-436
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the effect and toxicity profile of recombinant human interleukin 11(rhIL-11) on the platelet after hematopoietic stem cell transplantation in patients with leukemia.
METHODS:Twenty-four patients with acute or chronic leukemia treated by allogeneic peripheral blood stem cell transplantation (PBSCT) were randomly divided into a test group and a control group. The patients in the test group were treated with rhIL-11 since the 13th day after PBSCT (1.5mg/d),while the control group were given symptomatic treatment.
RESULTS:The average time for the platelet to recover to the level of 20 x 10(9)/L was 20.8 days in the test group, and 26.0 days in control group respectively, there was significant difference (P<0.01). The average time for the platelet to recover to the level of 50 x 10(9)/L was 25.7 days in the test group, and 32.3 days in the control group respectively, there was also significant difference (P<0.01). The average time for the platelet transfusion was 2.2 in the test group, 4.1 in the control group, and there was significantly different (P<0.01). The average number of megakaryocytes was 12.2 in the test group, 4.8 in the control group on 30th day after the transplantation,and there was significant difference(P<0.01). The main side effects of rhIL-11 were nausea, vomit, debility, headache, dizzy and pain of injection site, and the degree was all Iapproximately II grade.
CONCLUSION:rhIL-11 has definite recuperative effect on the recovery of the platelet after PBSCT. There is little side effect, and it can be accepted.
